Upstream Bio Executives Dump Shares Just Days Before Breakthrough Clinical Results — What It Means for Investors
Upstream Bio insider sell‑to‑cover activity signals routine tax moves, not confidence shifts, while the March 23 Phase‑2 results could spark a rally.
2 minutes to read